Folia expands patient-reported platform to MG
Smartphone app also adds the neurological conditions MS and Huntington's disease
Patients’ daily experiences will contribute to obtaining comprehensive data on disease progression and treatment response, which are expected to contribute to improving diagnosis and care.
“We’re excited to expand our work to harness the power of the observations that people make when living with [multiple sclerosis], MG, and [Huntington’s disease],” Nell Meosky Luo, CEO and founder of Folia Health, said in a press release.
Folia developed a health technology platform that enables patients to securely collect data about their condition at home. That includes recording and tracking their health observations as a way of measuring the variability of their signs and symptoms, disease flare events, and treatment usage.
The platform includes a daily journal where patients can easily track all their daily needs, an observation tracking where they can rapidly log their symptoms, and a treatment tracking feature with which they may group treatments together. Patients also may use the platform for treatment scheduling, and capture other important details on their health, including flares.
According to the company, more than 600 different health conditions are being tracked through Folia’s platform. Its use now has been expanded to people with MG and two neurological diseases: multiple sclerosis and Huntington’s disease.
The platform is completely customizable so that patients may easily track and visualize their preferred and most important health data. It also allows patients to share insights with their physicians, who play an active and central role in their care, and to decide whether and when they can contribute to research studies and perhaps be compensated for that.
“The positive feedback we’ve received from our existing users underscores the transformative potential of enabling people to capture their own home-reported outcomes as actionable insights,” Luo said.
Creating a full picture of the disease
Researchers can combine patient-generated data gathered through Folia’s platform with that obtained from other real-world data sources, such as patient registries and wearable devices, to create a full picture of the disease and start working on the development of new personalized therapies for it.
“As we continue to build these user cohorts, Folia Health looks forward to opportunities to conduct observational research studies in [multiple sclerosis], MG, and [Huntington’s disease],” said Connie Zhang, director of research programs at Folia Health.
“We believe in the power of collaboration to drive meaningful change in these complex conditions,” Zhang said.